EMBARGOED FOR RELEASE UNTIL 4 PM ET, January 07, 2013

Study: Parkinson’s Disease Itself Does Not Increase Risk of Gambling, Shopping Addiction

MINNEAPOLIS -

Parkinson’s disease itself does not increase the risk of impulse control problems such as compulsive gambling and shopping that have been seen in people taking certain drugs for , according to new research published in the January 8, 2013, print issue of Neurology®, the medical journal of the . “We’ve known for some time that these behaviors are more common in people taking certain Parkinson’s medications, but we haven’t known if the disease itself leads to an increased risk of these behaviors,” said study author Daniel Weintraub, MD, of the University of Pennsylvania Perelman School of Medicine in Philadelphia. The study involved 168 people who had recently been diagnosed with Parkinson’s disease and had not yet taken any medications for the disease. They were compared to 143 people of similar ages who did not have the disease. The participants were given a questionnaire asking how often they had impulse control symptoms such as compulsive gambling, shopping, sexual behavior or eating. Participants were also asked about aimless wandering, punding (which is excessive repetition of non-goal directed activity, such as continual handling and sorting of common objects) and hobbyism (the compulsive pursuit of a hobby such as collecting, cleaning or excessive Internet use). Those with Parkinson’s disease were no more or less likely to have the impulse control symptoms than those without the disease, with about 20 percent of each group having symptoms. “These results provide further evidence that impulse control disorders that occur in people with Parkinson’s disease are related to the exposure to the dopamine-related drugs, not just the disease itself,” Weintraub said. “More long-term studies are needed to determine if the 20 percent of people who have some symptoms of these disorders are more likely to develop impulse control disorders once they start treatment for Parkinson’s.” The study was supported by the Parkinson’s Progression Markers Initiative, a public-private partnership funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners including Abbott, Biogen Idec., F. Hoffman-La Roche Ltd., GE Healthcare, Genentech and Pfizer Inc. To learn more about Parkinson’s disease, visit .

The ��ɫ����, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy. For more information about the ��ɫ����, or find us on , , and .